Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics

Fineline Cube Jul 3, 2026
Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Shandong Boan Biotechnology Secures NMPA Approval for Phase II Trial of BA1106/BA1104 Combination in NSCLC, China’s First Non-IL-2-Blocking Anti-CD25 Antibody

Fineline Cube Jul 3, 2026
Company Drug

Bio-sincerity Secures NMPA Clinical Trial Approval for BIOS0629-109, Novel XPO1 Inhibitor for Advanced Malignant Tumors

Fineline Cube Jul 3, 2026
Company Drug

Sanofi’s Dupixent Receives Priority Review for Prurigo Nodosa Treatment

Fineline Cube Mar 6, 2023

French pharmaceutical major Sanofi (NASDAQ: SNY) has announced that it has received priority review status...

Policy / Regulatory

China’s Premier Li Keqiang Highlights Economic and Social Advances in Annual Report

Fineline Cube Mar 6, 2023

Premier Li Keqiang delivered his annual Government Work Report at the “Two Sessions” meeting, which...

Company Drug

Eli Lilly’s Retevmo Launched in China by Innovent Biologics

Fineline Cube Mar 6, 2023

Eli Lilly & Co’s (NYSE: LLY) Retevmo (selpercatinib) has been officially launched in the Chinese...

Company Deals

QL Biopharm Raises Series B Funding for Protein Drug Development

Fineline Cube Mar 6, 2023

QL Biopharm, a Beijing-based developer of Escherichia coli-based protein drugs, has reportedly raised RMB 100...

Company Drug

Huahai Pharma’s HB0025 Receives NMPA Approval for Clinical Trials

Fineline Cube Mar 6, 2023

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that it has received clinical...

Company Drug

Hengrui’s Adebrelimab Receives NMPA Approval for Lung Cancer Treatment

Fineline Cube Mar 6, 2023

Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced that it has received marketing approval from the...

Company Deals

Siyi Intelligence Raises Series A Funding for Neural Rehabilitation Solutions

Fineline Cube Mar 6, 2023

Siyi Intelligence, a developer of soft rehabilitation robots based in Shanghai, has reportedly raised close...

Company Drug

Sino Biopharmaceutical’s Bevacizumab Biosimilar Approved by NMPA

Fineline Cube Mar 6, 2023

Sino Biopharmaceutical Ltd (HKG: 1177) has announced that it has received marketing approval from the...

Company Drug

Mabwell’s 9MW3911 Monoclonal Antibody Accepted for NMPA Review

Fineline Cube Mar 6, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that a clinical trial filing...

Company Drug

Venus Medtech Completes Patient Enrollment for Liwen RF Ablation System Study

Fineline Cube Mar 6, 2023

China-based Venus Medtech (Hangzhou) Inc. (HKG: 2500) has announced that all patients have been successfully...

Company Deals

PulseCare Raises Pre-Series A Funding for Minimally Invasive Treatment Devices

Fineline Cube Mar 6, 2023

PulseCare, a Shenzhen-based maker of minimally and non-invasive treatment devices, has reportedly raised “tens of...

Company Deals R&D

HKUST and PhIRDA Sign MoU to Establish Innovation Centers

Fineline Cube Mar 4, 2023

The Hong Kong University of Science and Technology (HKUST) and the China Pharmaceutical Innovation and...

Policy / Regulatory

China Releases Blue Book on Medical Insurance Fund Supervision

Fineline Cube Mar 3, 2023

The China Health Insurance and Social Sciences Academic Press has jointly released the “Blue Book...

Policy / Regulatory

NHC Recommends Simcere and Junshi COVID-19 Therapies in Updated Guidelines

Fineline Cube Mar 3, 2023

The National Health Commission (NHC) has released a notification including Simcere Pharmaceutical Group’s (HKG: 2096)...

Company Deals

ClinChoice Acquires Cromsource to Expand Global CRO Footprint

Fineline Cube Mar 3, 2023

Sino-US Contract Research Organization (CRO) ClinChoice Medical Development has announced the acquisition of Cromsource S.r.l.,...

Company Drug

Atom Bioscience’s ABP-671 Shows Positive Phase IIa Results in Gout Treatment

Fineline Cube Mar 3, 2023

China-based Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd) has announced positive results from...

Company Deals

Echo Biotech Secures Series A++ Funding for Exosomes Drug Development

Fineline Cube Mar 3, 2023

Echo Biotech, a Beijing-based exosomes drug developer, has reportedly raised “tens of millions” of renminbi...

Company Medical Device

AffaMed Technologies Completes First Patient Implantation for MINI WELL IOL

Fineline Cube Mar 3, 2023

AffaMed Technologies, a joint venture between AffaMed Therapeutics and SIFI S.p.A., has announced the completion...

Company Drug

CSPC Pharmaceutical Initiates Phase III Study for Mitoxantrone Liposome in Nasopharyngeal Carcinoma

Fineline Cube Mar 3, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced the first patient dosing in a...

Policy / Regulatory

National VBP Tender Round 8 to Be Held in Hainan with 40 Drugs Bidding

Fineline Cube Mar 3, 2023

The National Allied Procurement Office has released a notification regarding the Round 8 of the...

Posts pagination

1 … 579 580 581 … 690

Recent updates

  • Shandong Boan Biotechnology Secures NMPA Approval for Phase II Trial of BA1106/BA1104 Combination in NSCLC, China’s First Non-IL-2-Blocking Anti-CD25 Antibody
  • CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics
  • Bio-sincerity Secures NMPA Clinical Trial Approval for BIOS0629-109, Novel XPO1 Inhibitor for Advanced Malignant Tumors
  • Novartis Secures EU Approval for Itvisma, First Gene Replacement Therapy for Broad SMA Population Including Patients Two Years and Older
  • Ocumension Therapeutics Secures NMPA Approval for OT-502, China’s First Single-Dose Sustained-Release Intraocular Steroid for Postoperative Inflammation
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shandong Boan Biotechnology Secures NMPA Approval for Phase II Trial of BA1106/BA1104 Combination in NSCLC, China’s First Non-IL-2-Blocking Anti-CD25 Antibody

Company Deals

CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics

Company Drug

Bio-sincerity Secures NMPA Clinical Trial Approval for BIOS0629-109, Novel XPO1 Inhibitor for Advanced Malignant Tumors

Company Drug

Novartis Secures EU Approval for Itvisma, First Gene Replacement Therapy for Broad SMA Population Including Patients Two Years and Older

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.